Cara Therapeutics to Present at the Virtual BofA Securities 2020 Health Care Conference

Rhea-AI Summary

Cara Therapeutics (Nasdaq: CARA) announced that its President and CEO, Derek Chalmers, and Chief Medical Officer, Joana Goncalves, will participate in a fireside chat at the virtual BofA Securities 2020 Health Care Conference on May 14, 2020, at 9:00 a.m. ET. The event will focus on the company’s innovative treatments targeting peripheral kappa opioid receptors to alleviate pruritus. A live webcast will be available on the company's website under 'Events & Presentations', with an archived recording accessible for 30 days.

STAMFORD, Conn., May 07, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, today announced that Derek Chalmers, Ph.D., D.Sc., President and Chief Executive Officer, and Joana Goncalves, M.D., Chief Medical Officer, will participate in a fireside chat at the virtual BofA Securities 2020 Health Care Conference on Thursday, May 14, 2020 at 9:00 a.m. ET.

A live webcast of the presentation can be accessed under "Events & Presentations" in the News & Investors section of the Company's website at www.CaraTherapeutics.com. An archived webcast recording will be available on the Cara website for approximately 30 days.

About Cara Therapeutics

Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs. Cara is developing a novel and proprietary class of product candidates, led by KORSUVA™ (CR845/difelikefalin), a first-in-class KOR agonist that targets the body’s peripheral nervous system, as well as certain immune cells. In two Phase 3 trials, KORSUVA Injection has demonstrated statistically significant reductions in itch intensity and concomitant improvement in quality of life measures in hemodialysis patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP). Oral KORSUVA is in Phase 2 trials for the treatment of pruritus in patients with CKD, atopic dermatitis and primary biliary cholangitis.

The FDA has conditionally accepted KORSUVA™ as the trade name for difelikefalin injection. CR845/difelikefalin is an investigational drug product and its safety and efficacy have not been fully evaluated by any regulatory authority.

INVESTOR CONTACT:
Jane Urheim
Stern Investor Relations, Inc.
212-362-1200
jane.urheim@SternIR.com

MEDIA CONTACT:
Annie Starr
6 Degrees
973-415-8838
astarr@6degreespr.com

FAQ

What is the date and time of Cara Therapeutics' participation in the BofA Securities 2020 Health Care Conference?

Cara Therapeutics will participate in the BofA Securities 2020 Health Care Conference on May 14, 2020, at 9:00 a.m. ET.

How can I access the live webcast of the Cara Therapeutics presentation?

The live webcast of the Cara Therapeutics presentation can be accessed in the 'Events & Presentations' section of their website.

What is the focus of Cara Therapeutics as a biopharmaceutical company?

Cara Therapeutics focuses on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors.

What is KORSUVA and its significance in Cara Therapeutics' clinical trials?

KORSUVA is a first-in-class KOR agonist developed by Cara Therapeutics, shown to significantly reduce itch intensity in kidney disease patients in Phase 3 trials.

Is KORSUVA approved by the FDA?

The FDA has conditionally accepted KORSUVA as the trade name for difelikefalin injection, but its safety and efficacy are still under evaluation.